[Clinical application of KM 2210 (estradiol-chlorambucil) in patients with advanced prostatic carcinoma].
KM 2210, a combination product of 17 beta-estradiol and chlorambucil, was administered to 15 patients with advanced (stage C and D) prostatic carcinoma. We studied the clinical efficacy and the drug concentration in the blood and prostatic tissues. The administered doses were 100 mg or 150 mg p.o., in 2 or 3 divided doses/day (or every other day in a few cases) for periods ranging from 30 to 369 days; the maximum total dose was 42.5 g. Objective clinical responses, according to the criteria by Shida et al., were observed in 6 (40%) patients. Side effects included gastrointestinal symptoms, e.g. loss of appetite or nausea, anemia and leukopenia. No obvious hepatic disorder was observed.
D000368:Aged; D000818:Animals; D002648:Child; D002699:Chlorambucil / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D051381:Rats
D002699:Chlorambucil; D004958:Estradiol; C036613:bestrabucil